Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Target cell ligands at the immunological synapse" refers to a wide and heterogeneous group of molecules expressed on the surface of a target cell (such as an antigen-presenting cell, infected cell, or tumor cell) that interact with receptors on lymphocytes (like T cells, B cells, or natural killer cells) across the immunological synapse. Key classes of these ligands include major histocompatibility complex (MHC) molecules (presenting antigenic peptides), adhesion molecules (such as ICAM-1), costimulatory molecules (such as CD80 and CD86), as well as other immune checkpoint ligands (e.g., PD-L1, MICA/B, and others). The multiplicity and diversity of these ligands means the term does not refer to a specific entity but rather to the collective set of molecules mediating immune recognition, activation, and effector responses at the cell-cell junction known as the immunological synapse[2][5][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Target cell ligands at the immunological synapse.